Literature DB >> 24330321

Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population.

Michael J Bly1, Stephan F Taylor, Gregory Dalack, Rodica Pop-Busui, Kyle J Burghardt, Simon J Evans, Melvin I McInnis, Tyler B Grove, Robert D Brook, Sebastian K Zöllner, Vicki L Ellingrod.   

Abstract

OBJECTIVE: Since a poor diet is often cited as a contributor to metabolic syndrome for subjects diagnosed with bipolar disorder and schizophrenia, we sought to examine dietary intake, cigarette smoking, and physical activity in these populations and compare them with those for the general population.
METHODS: Individuals diagnosed with bipolar disorder (n = 116) and schizophrenia (n = 143) were assessed for dietary intake, lifestyle habits, and metabolic syndrome and compared to age-, gender-, and race-matched subjects from the National Health and Nutrition Examination Survey (NHANES) 1999-2000. Additionally, matched subgroups within the patient populations were compared to elicit any differences.
RESULTS: As expected, the metabolic syndrome rate was higher in the samples with bipolar disorder (33%) and schizophrenia (47%) compared to matched NHANES controls (17% and 11%, respectively), and not different between the patient groups. Surprisingly, both subjects with bipolar disorder and those with schizophrenia consumed fewer total calories, carbohydrates and fats, as well as more fiber (p < 0.03), compared to NHANES controls. No dietary or activity differences between patient participants with and without metabolic syndrome were found. Subjects with schizophrenia had significantly lower total and low-density cholesterol levels (p < 0.0001) compared to NHANES controls. Subjects with bipolar disorder smoked less (p = 0.001), exercised more (p = 0.004), and had lower body mass indexes (p = 0.009) compared to subjects with schizophrenia.
CONCLUSIONS: Counter to predictions, few dietary differences could be discerned between schizophrenia, bipolar disorder, and NHANES control groups. The subjects with bipolar disorder exhibited healthier behaviors than the patients with schizophrenia. Additional research regarding metabolic syndrome mechanisms, focusing on non-dietary contributions, is needed.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  atypical antipsychotics; bipolar disorder; dietary intake; metabolic syndrome; schizophrenia

Mesh:

Year:  2013        PMID: 24330321      PMCID: PMC4023536          DOI: 10.1111/bdi.12160

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  55 in total

Review 1.  Antidepressants and body weight: a comprehensive review and meta-analysis.

Authors:  Alessandro Serretti; Laura Mandelli
Journal:  J Clin Psychiatry       Date:  2010-10       Impact factor: 4.384

Review 2.  Antipsychotic drugs and obesity.

Authors:  Christoph U Correll; Todd Lencz; Anil K Malhotra
Journal:  Trends Mol Med       Date:  2010-12-22       Impact factor: 11.951

Review 3.  Obesity, physical inactivity, and risk for cardiovascular disease.

Authors:  Patricia M Dubbert; Teresa Carithers; Anne E Sumner; Krista A Barbour; Bobby L Clark; John E Hall; Errol D Crook
Journal:  Am J Med Sci       Date:  2002-09       Impact factor: 2.378

Review 4.  Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions.

Authors:  James L Megna; Thomas L Schwartz; Umar A Siddiqui; Mariela Herrera Rojas
Journal:  Ann Clin Psychiatry       Date:  2011-05       Impact factor: 1.567

5.  The Automated Self-Administered 24-hour dietary recall (ASA24): a resource for researchers, clinicians, and educators from the National Cancer Institute.

Authors:  Amy F Subar; Sharon I Kirkpatrick; Beth Mittl; Thea Palmer Zimmerman; Frances E Thompson; Christopher Bingley; Gordon Willis; Noemi G Islam; Tom Baranowski; Suzanne McNutt; Nancy Potischman
Journal:  J Acad Nutr Diet       Date:  2012-06-15       Impact factor: 4.910

6.  The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.

Authors:  Jonathan M Meyer; Henry A Nasrallah; Joseph P McEvoy; Donald C Goff; Sonia M Davis; Miranda Chakos; Jayendra K Patel; Richard S E Keefe; T Scott Stroup; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2005-08-24       Impact factor: 4.939

7.  Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs.

Authors:  Nancy C Andreasen; Marcus Pressler; Peg Nopoulos; Del Miller; Beng-Choon Ho
Journal:  Biol Psychiatry       Date:  2009-11-07       Impact factor: 13.382

8.  Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants.

Authors:  Vicki L Ellingrod; Del D Miller; Stephan F Taylor; Jessica Moline; Timothy Holman; Jane Kerr
Journal:  Schizophr Res       Date:  2007-10-31       Impact factor: 4.939

9.  Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study.

Authors:  Fuminari Misawa; Keiko Shimizu; Yasuo Fujii; Ryouji Miyata; Fumio Koshiishi; Mihoko Kobayashi; Hirokazu Shida; Yoshiyo Oguchi; Yasuyuki Okumura; Hiroto Ito; Mami Kayama; Haruo Kashima
Journal:  BMC Psychiatry       Date:  2011-07-26       Impact factor: 3.630

10.  Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states.

Authors:  Craig W Colton; Ronald W Manderscheid
Journal:  Prev Chronic Dis       Date:  2006-03-15       Impact factor: 2.830

View more
  19 in total

1.  An Untargeted Metabolomics Analysis of Antipsychotic Use in Bipolar Disorder.

Authors:  Kyle J Burghardt; Simon J Evans; Kristen M Wiese; Vicki L Ellingrod
Journal:  Clin Transl Sci       Date:  2015-08-27       Impact factor: 4.689

2.  Effects of Atypical Antipsychotic Treatment and Resistant Starch Supplementation on Gut Microbiome Composition in a Cohort of Patients with Bipolar Disorder or Schizophrenia.

Authors:  Stephanie A Flowers; Nielson T Baxter; Kristen M Ward; A Zarina Kraal; Melvin G McInnis; Thomas M Schmidt; Vicki L Ellingrod
Journal:  Pharmacotherapy       Date:  2019-02-03       Impact factor: 4.705

3.  High Prevalence of Metabolic Syndrome Among Adolescents and Young Adults With Bipolar Disorder.

Authors:  Christine Li; Boris Birmaher; Brian Rooks; Mary Kay Gill; Heather Hower; David A Axelson; Daniel P Dickstein; Tina R Goldstein; Fangzi Liao; Shirley Yen; Jeffrey Hunt; Satish Iyengar; Neal D Ryan; Michael A Strober; Martin B Keller; Benjamin I Goldstein
Journal:  J Clin Psychiatry       Date:  2019-07-30       Impact factor: 4.384

4.  Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls.

Authors:  Christoph U Correll; Marco Solmi; Nicola Veronese; Beatrice Bortolato; Stella Rosson; Paolo Santonastaso; Nita Thapa-Chhetri; Michele Fornaro; Davide Gallicchio; Enrico Collantoni; Giorgio Pigato; Angela Favaro; Francesco Monaco; Cristiano Kohler; Davy Vancampfort; Philip B Ward; Fiona Gaughran; André F Carvalho; Brendon Stubbs
Journal:  World Psychiatry       Date:  2017-06       Impact factor: 49.548

5.  Polygenic risk for type 2 diabetes mellitus among individuals with psychosis and their relatives.

Authors:  Jaya L Padmanabhan; Pranav Nanda; Neeraj Tandon; Suraj S Mothi; Nicolas Bolo; Steven McCarroll; Brett A Clementz; Elliot S Gershon; Godfrey D Pearlson; John A Sweeney; Carol A Tamminga; Matcheri S Keshavan
Journal:  J Psychiatr Res       Date:  2016-02-23       Impact factor: 4.791

6.  High H1-affinity antidepressants and risk of metabolic syndrome in bipolar disorder.

Authors:  Virginio Salvi; Francesco Barone-Adesi; Virginia D'Ambrosio; Umberto Albert; Giuseppe Maina
Journal:  Psychopharmacology (Berl)       Date:  2015-09-26       Impact factor: 4.530

7.  Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis.

Authors:  Davy Vancampfort; Brendon Stubbs; Alex J Mitchell; Marc De Hert; Martien Wampers; Philip B Ward; Simon Rosenbaum; Christoph U Correll
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548

8.  Metabolic syndrome, serious mental illnesses & lifestyle.

Authors:  R Padmavati
Journal:  Indian J Med Res       Date:  2016-04       Impact factor: 2.375

9.  Effect of lifestyle coaching versus care coordination versus treatment as usual in people with severe mental illness and overweight: Two-years follow-up of the randomized CHANGE trial.

Authors:  Ane Storch Jakobsen; Helene Speyer; Hans Christian Brix Nørgaard; Mette Karlsen; Merete Birk; Carsten Hjorthøj; Ole Mors; Jesper Krogh; Christian Gluud; Charlotta Pisinger; Merete Nordentoft
Journal:  PLoS One       Date:  2017-10-06       Impact factor: 3.240

10.  Cohort Profile: The Heinz C. Prechter Longitudinal Study of Bipolar Disorder.

Authors:  Melvin G McInnis; Shervin Assari; Masoud Kamali; Kelly Ryan; Scott A Langenecker; Erika F H Saunders; Kritika Versha; Simon Evans; K Sue O'Shea; Emily Mower Provost; David Marshall; Daniel Forger; Patricia Deldin; Sebastian Zoellner
Journal:  Int J Epidemiol       Date:  2018-02-01       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.